Articles from Slingshot Biosciences

Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing programs by assuring the reproducibility of results. The use of TruCytes™ Potency CD20 controls provides consistent mechanism-of-action (MoA) potency readouts, while TruCytes™ CD34 Stem Cell Gating Controls assure consistent and repeatable standardization of CD34 enumeration in flow cytometry.

Slingshot Biosciences, a leader in precision-engineered cell mimics, has appointed Glenn Bilawsky as Chief Executive Officer. He succeeds Founder and former CEO Jeffrey Kim, PhD, who will remain actively involved as a Senior Advisor and Board Director.

Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell mimics specifically designed for functional CAR-T potency assays. TruCytes Potency cell mimics offer a customizable, scalable, and efficient alternative to cell line target cells. This helps CAR-T developers accelerate assay validation and lot release, while avoiding the operational burden, variability and chain-of-custody challenges of custom cell lines.

Slingshot Biosciences today announced the addition of Nimisha Srivastava, Ph.D., as Chief Operations Officer. Dr. Srivastava brings more than 20 years of experience in nanofluidics, synthetic biology technology development, and operational scale-up, as well as a proven track record of building high-performing technical teams.

In response to strong customer demand, Slingshot Biosciences is introducing a groundbreaking portfolio of products that will transform the landscape of analytical precision in cell therapy. Its first products in this category are aimed at solving quality control challenges that plague current cell therapy development and manufacturing processes.

Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform for customizing cell and cell line mimics, today announced the closing of $11 million in a Series A3 financing.

Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform, today announced the closing of $23 million in a Series A financing. The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital. The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies. Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors. Slingshot will also invest heavily in its broader adoptive cell therapy and therapeutics platform with this growth financing.